Antibiotics from Discovery to Crisis: An Antibiotic History and the Global Emergency of Antimicrobial Resistance | IJLTEMAS
00
Days
00
Hrs
00
Min
00
Sec
Submit Your Paper

Antibiotics from Discovery to Crisis: An Antibiotic History and the Global Emergency of Antimicrobial Resistance

Authors

J.S. Billion

Research Scholar, PG and Research Department of Microbiology, KMG College of Arts and Science (Autonomous), Gudiyattam, Tamil Nadu, India (India)

Dr. D. Manikandan

PG and Research Department of Microbiology, KMG College of Arts and Science (Autonomous), Gudiyattam, Tamil Nadu, India (India)

M. Chatiyaa

PG and Research Department of Microbiology, KMG College of Arts and Science (Autonomous), Gudiyattam, Tamil Nadu, India (India)

Article Information

DOI: 10.51583/IJLTEMAS.2026.151000120

Subject Category: Microbiology

Volume/Issue: 15/10 | Page No: 1488-1499

Publication Timeline

Submitted: 2026-10-26

Accepted: 2026-10-31

Published: 2026-11-17

Abstract

In the twentieth century, antibiotics revolutionized medicine by making previously lethal infections curable and by enabling organ transplantation, chemotherapy, surgery, and newborn care. Less than a century after penicillin entered clinical use, however, antimicrobial resistance (AMR) has become one of the greatest threats to global health. This review traces the history of antibiotics and examines how the present resistance crisis arose, what it costs, and how it might be addressed. It is a narrative review based on a structured search of PubMed, Scopus, Web of Science, and Google Scholar for literature published up to date, supplemented by reports from the World Health Organization (WHO). It covers the pre-antibiotic period, the “golden age” of discovery (1940s–1960s), the “discovery void” that followed, and the current era of renewed but fragile innovation. The molecular mechanisms of resistance, the human, animal, and environmental drivers of the crisis, the worldwide burden of resistant infections, the economic barriers that have weakened the antibiotic pipeline, and the proposed solutions are summarized in five tables, including a timeline of major milestones, the WHO 2024 bacterial priority pathogens list, and a comparative appraisal of interventions. Bacterial AMR was directly responsible for approximately 1.27 million deaths and was associated with approximately 4.95 million deaths in 2019; the corresponding estimates for 2021 were 1.14 million and 4.71 million, and attributable deaths could reach approximately 1.9 million per year by 2050 if current trends continue. The burden falls disproportionately on older adults and on people in sub-Saharan Africa and South Asia. The crisis reflects a biological inevitability that is amplified by the overuse and misuse of antibiotics, inadequate infection control, and market failure. Our appraisal indicates that no single intervention is sufficient and that major evidence gaps remain, particularly for diagnostics, alternative therapies, and economic incentives in low- and middle-income countries. A coordinated One Health response that combines stewardship, surveillance, new discoveries, alternative therapies, and new economic incentives is necessary to preserve the effectiveness of antibiotics for future generations.

Keywords

antibiotics; antimicrobial resistance; ESKAPE pathogens; antimicrobial stewardship; One Health; WHO priority pathogens; antibiotic discovery

Downloads

References

1. Abraham, E. P., & Chain, E. (1940). An enzyme from bacteria able to destroy penicillin. Nature, 146, 837. https://doi.org/10.1038/146837a0 [Google Scholar] [Crossref]

2. Aminov, R. (2017). History of antimicrobial drug discovery: Major classes and health impact. Biochemical Pharmacology, 133, 4–19. https://doi.org/10.1016/j.bcp.2016.10.001 [Google Scholar] [Crossref]

3. Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0 [Google Scholar] [Crossref]

4. Årdal, C., Balasegaram, M., Laxminarayan, R., McAdams, D., Outterson, K., Rex, J. H., & Sumpradit, N. (2020). Antibiotic development: Economic, regulatory and societal challenges. Nature Reviews Microbiology, 18(5), 267–274. https://doi.org/10.1038/s41579-019-0293-3 [Google Scholar] [Crossref]

5. Aslam, B., Wang, W., Arshad, M. I., Khurshid, M., Muzammil, S., Rasool, M. H., Nisar, M. A., Alvi, R. F., Aslam, M. A., Qamar, M. U., Salamat, M. K. F., & Baloch, Z. (2018). Antibiotic resistance: A rundown of a global crisis. Infection and Drug Resistance, 11, 1645–1658. [Google Scholar] [Crossref]

6. https://doi.org/10.2147/IDR.S173867 [Google Scholar] [Crossref]

7. Brown, E. D., & Wright, G. D. (2016). Antibacterial drug discovery in the resistance era. Nature, 529(7586), 336–343. https://doi.org/10.1038/nature17042 [Google Scholar] [Crossref]

8. Browne, A. J., Chipeta, M. G., Haines-Woodhouse, G., Kumaran, E. P. A., Hamadani, B. H. K., Zaraa, S., et al. (2021). Global antibiotic consumption and usage in humans, 2000–18: A spatial modelling study. The Lancet Planetary Health, 5(12), e893–e904. https://doi.org/10.1016/S2542-5196(21)00280-1 [Google Scholar] [Crossref]

9. Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., Cardo, D., & Fridkin, S. K. (2003). Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. New England Journal of Medicine, 348(14), 1342–1347. https://doi.org/10.1056/NEJMoa025025 [Google Scholar] [Crossref]

10. Christaki, E., Marcou, M., & Tofarides, A. (2020). Antimicrobial resistance in bacteria: Mechanisms, evolution, and persistence. Journal of Molecular Evolution, 88(1), 26–40. [Google Scholar] [Crossref]

11. https://doi.org/10.1007/s00239-019-09914-3 [Google Scholar] [Crossref]

12. Dadgostar, P. (2019). Antimicrobial resistance: Implications and costs. Infection and Drug Resistance, 12, 3903–3910. https://doi.org/10.2147/IDR.S234610 [Google Scholar] [Crossref]

13. Darby, E. M., Trampari, E., Siasat, P., Gaya, M. S., Alav, I., Webber, M. A., & Blair, J. M. A. (2023). Molecular mechanisms of antibiotic resistance revisited. Nature Reviews Microbiology, 21(5), 280–295. https://doi.org/10.1038/s41579-022-00820-y [Google Scholar] [Crossref]

14. Gaynes, R. (2017). The discovery of penicillin—New insights after more than 75 years of clinical use. Emerging Infectious Diseases, 23(5), 849–853. https://doi.org/10.3201/eid2305.161556 [Google Scholar] [Crossref]

15. GBD 2021 Antimicrobial Resistance Collaborators. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: A systematic analysis with forecasts to 2050. The Lancet, 404(10459), 1199–1226. https://doi.org/10.1016/S0140-6736(24)01867-1 [Google Scholar] [Crossref]

16. Hutchings, M. I., Truman, A. W., & Wilkinson, B. (2019). Antibiotics: Past, present and future. Current Opinion in Microbiology, 51, 72–80. https://doi.org/10.1016/j.mib.2019.10.008 [Google Scholar] [Crossref]

17. Jevons, M. P. (1961). “Celbenin”-resistant staphylococci. British Medical Journal, 1(5219), 124–125. https://doi.org/10.1136/bmj.1.5219.124-a [Google Scholar] [Crossref]

18. Klein, E. Y., Van Boeckel, T. P., Martinez, E. M., Pant, S., Gandra, S., Levin, S. A., Goossens, H., & Laxminarayan, R. (2018). Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proceedings of the National Academy of Sciences, 115(15), E3463–E3470. https://doi.org/10.1073/pnas.1717295115 [Google Scholar] [Crossref]

19. Kwon, J. H., & Powderly, W. G. (2021). The post-antibiotic era is here. Science, 373(6554), 471. https://doi.org/10.1126/science.abl5997 [Google Scholar] [Crossref]

20. Larsson, D. G. J., & Flach, C.-F. (2022). Antibiotic resistance in the environment. Nature Reviews Microbiology, 20(5), 257–269. https://doi.org/10.1038/s41579-021-00649-x [Google Scholar] [Crossref]

21. Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016). Access to effective antimicrobials: A worldwide challenge. The Lancet, 387(10014), 168–175. https://doi.org/10.1016/S0140-6736(15)00474-2 [Google Scholar] [Crossref]

22. Leclercq, R., Derlot, E., Duval, J., & Courvalin, P. (1988). Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. New England Journal of Medicine, 319(3), 157–161. [Google Scholar] [Crossref]

23. https://doi.org/10.1056/NEJM198807213190307 [Google Scholar] [Crossref]

24. Lewis, K. (2020). The science of antibiotic discovery. Cell, 181(1), 29–45. [Google Scholar] [Crossref]

25. https://doi.org/10.1016/j.cell.2020.02.056 [Google Scholar] [Crossref]

26. Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature, 517(7535), 455–459. [Google Scholar] [Crossref]

27. https://doi.org/10.1038/nature14098 [Google Scholar] [Crossref]

28. Liu, G., Catacutan, D. B., Rathod, K., Swanson, K., Jin, W., Mohammed, J. C., et al. (2023). Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii. Nature Chemical Biology, 19(11), 1342–1350. https://doi.org/10.1038/s41589-023-01349-8 [Google Scholar] [Crossref]

29. Liu, Y.-Y., Wang, Y., Walsh, T. R., Yi, L.-X., Zhang, R., Spencer, J., et al. (2016). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. The Lancet Infectious Diseases, 16(2), 161–168. [Google Scholar] [Crossref]

30. https://doi.org/10.1016/S1473-3099(15)00424-7 [Google Scholar] [Crossref]

31. Mancuso, G., Midiri, A., Gerace, E., & Biondo, C. (2021). Bacterial antibiotic resistance: The most critical pathogens. Pathogens, 10(10), 1310. https://doi.org/10.3390/pathogens10101310 [Google Scholar] [Crossref]

32. Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021). Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry, 5(10), 726–749. https://doi.org/10.1038/s41570-021-00313-1 [Google Scholar] [Crossref]

33. Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019). Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review. Frontiers in Microbiology, 10, 539. https://doi.org/10.3389/fmicb.2019.00539 [Google Scholar] [Crossref]

34. Munita, J. M., & Arias, C. A. (2016). Mechanisms of antibiotic resistance. Microbiology Spectrum, 4(2). https://doi.org/10.1128/microbiolspec.VMBF-0016-2015 [Google Scholar] [Crossref]

35. Pulingam, T., Parumasivam, T., Gazzali, A. M., Sulaiman, A. M., Chee, J. Y., Lakshmanan, M., Chin, C. F., & Sudesh, K. (2022). Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. European Journal of Pharmaceutical Sciences, 170, 106103. https://doi.org/10.1016/j.ejps.2021.106103 [Google Scholar] [Crossref]

36. Rice, L. B. (2008). Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. The Journal of Infectious Diseases, 197(8), 1079–1081. https://doi.org/10.1086/533452 [Google Scholar] [Crossref]

37. Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. A. (2023). Antimicrobial resistance: A growing serious threat for global public health. Healthcare, 11(13), 1946. https://doi.org/10.3390/healthcare11131946 [Google Scholar] [Crossref]

38. Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., et al. (2020). A deep learning approach to antibiotic discovery. Cell, 180(4), 688–702.e13. [Google Scholar] [Crossref]

39. https://doi.org/10.1016/j.cell.2020.01.021 [Google Scholar] [Crossref]

40. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., et al. (2018). Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases, 18(3), 318–327. [Google Scholar] [Crossref]

41. https://doi.org/10.1016/S1473-3099(17)30753-3 [Google Scholar] [Crossref]

42. Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020). The global preclinical antibacterial pipeline. Nature Reviews Microbiology, 18(5), 275–285. https://doi.org/10.1038/s41579-019-0288-0 [Google Scholar] [Crossref]

43. Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., et al. (2021). Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. Journal of Infection and Public Health, 14(12), 1750–1766. https://doi.org/10.1016/j.jiph.2021.10.020 [Google Scholar] [Crossref]

44. United Nations General Assembly. (2024). Political declaration of the high-level meeting on antimicrobial resistance (A/79/L.2). United Nations. [Google Scholar] [Crossref]

45. Van Boeckel, T. P., Pires, J., Silvester, R., Zhao, C., Song, J., Criscuolo, N. G., Gilbert, M., Bonhoeffer, S., & Laxminarayan, R. (2019). Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science, 365(6459), eaaw1944. https://doi.org/10.1126/science.aaw1944 [Google Scholar] [Crossref]

46. World Bank. (2017). Drug-resistant infections: A threat to our economic future. World Bank. [Google Scholar] [Crossref]

47. World Health Organization. (2015). Global action plan on antimicrobial resistance. World Health Organization. [Google Scholar] [Crossref]

48. World Health Organization. (2023). AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. World Health Organization. [Google Scholar] [Crossref]

49. World Health Organization. (2024). WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. World Health Organization. [Google Scholar] [Crossref]

50. Yong, D., Toleman, M. A., Giske, C. G., Cho, H. S., Sundman, K., Lee, K., & Walsh, T. R. (2009). Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrobial Agents and Chemotherapy, 53(12), 5046–5054. https://doi.org/10.1128/AAC.00774-09 [Google Scholar] [Crossref]

Metrics

Views & Downloads

Similar Articles

Engineering,
Management &
Applied Science
Journal
(IJLTEMAS)
Published by RSIS International
Tower B, Suncity Success Tower
Golf Course Ext Rd, Sector 65
Gurugram, Haryana 122101, India
© 2026 IJLTEMAS · RSIS International. ISSN 2278-2540.